title: The impact of topiramate (Topamax®) therapy on the development of aggressive and/or agitated behavior.
abstract: The use of topiramate therapy to control the neuropsychiatric and behavioral disturbances in individuals with mental and/or developmental disabilities with co-occurring psychiatric disturbances has become a standard of practice in many long-term care assisted living facilities. With increased utilization of this anticonvulsant, there has been a rise in the number documented cases of agitation and/or aggressive behavior associated with topiramate therapy. It is the purpose of this article to explore the current literature documenting the connection between topiramate utilization and the development of aggressive and/or agitated behavior.
authors: Lufkin State Supported Living Center, Nacogdoches, TX 75965, USA. aofpharm420@hotmail.com
authors: Abimbola
authors: A
authors: Farinde
mesh_terms: D000328:Adult; D000374:Aggression / Q000523:psychology*; D000927:Anticonvulsants / Q000009:adverse effects*; D004827:Epilepsy / Q000188:drug therapy*; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced*; D011595:Psychomotor Agitation / Q000209:etiology* / Q000523:psychology; D000077236:Topiramate
chemical_list: D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose